VQW-765 Phase III Trial Fails, Vanda Puts Anxiety Drug on Hold

The VQW-765 Phase III trial has raised questions about the challenges of translating promising mid-stage clinical findings into successful late-stage outcomes.

Vanda Pharmaceuticals reported that its experimental drug for social anxiety disorder failed to demonstrate a significant improvement over placebo during a public-speaking stress test.

The company has put the development program on hold while it reviews the full dataset.

The setback is notable because an earlier Phase II study had suggested that the drug could reduce anxiety symptoms.

The late-stage trial was consistent with the earlier data, illustrating the inherent uncertainty in anxiety drug development and the need to establish efficacy in a larger population.

The Phase III study enrolled 546 adults across approximately 30 sites in the United States.

Vanda reported that the drug was safe and well tolerated, consistent with earlier studies, but that the trial missed its primary endpoint and a key secondary endpoint.

What Do the VQW-765 Clinical Trial Results Reveal?

VQW-765’s phase III trial was designed to validate the findings of a prior mid-stage trial, but it didn’t achieve its main goal, showing that promising early data don’t necessarily guarantee success at scale.

Key findings include:

• Primary endpoint missed: VQW-765 did not demonstrate reduced anxiety when compared to placebo in a public speaking stress test.
• Secondary endpoint missed: The study also failed to meet a key secondary goal in the broader population study.
• Safety profile maintained: Vanda said that the treatment was safe and consistent throughout the broader study.
• Program placed on hold: Vanda has placed the program on hold currently as it reviews the dataset to determine its next course of action.

Also Read: A Cure for Postpartum Depression - If You Can Afford It

What Happens Next for Vanda Pharmaceuticals’ Anxiety Drug?

Vanda Pharmaceuticals has paused the VQW-765 development program pending further analysis of the trial data.

The company has not announced a definitive discontinuation of the candidate in the reported update.

Subsequent steps will be determined after completely analyzing the trial data and determining if any variable can account for the discrepancies between Phase II and Phase III trials. 

Further conclusions would require additional information from the company; the available results do not establish why the treatment failed to meet its endpoints.

The setback also highlights the challenges facing clinical research into social anxiety disorder, where improvements in symptoms must be demonstrated using appropriate and reliable study measures.

For Vanda, the immediate priority is to evaluate the evidence before deciding whether the program has a viable path forward.

The VQW-765 Phase III trial outcome is a reminder that promising mid-stage findings must withstand rigorous late-stage testing.

Although the reported safety results were encouraging, the absence of demonstrated efficacy leaves the future of Vanda Pharmaceuticals’ anxiety drug program uncertain.